Program
Sinovac rabies vaccine
Its studies are mostly in Rabies, led by Sinovac Biotech.
Furthest: phase 3, since Jan 5, 20262 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sinovac Biotech | 21 open or running | phase 3since Jan 5, 2026 | Jan 5, 2026 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 5, 2026First study: phase 3 study in RabiesFirst studyNCT07357545 · 2,040 enrolled · China
- Feb 10, 2026Phase 3 study in RabiesNCT07416110 · 912 enrolled · China
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Sinovac rabies vaccine”name, by rule
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07416110Rabies · China | 3 | Active, not recruiting | Jul 15, 2026 | 912 |
| NCT07357545Rabies · China | 3 | Completed | Sep 21, 2022 | 2,040 |
How it is read
Names in the registry
- “Sinovac rabies vaccine”, 2 entries
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.